194 results about "Receptor modulator" patented technology

The disclosure provides methods the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and for treatment of psychiatric symptoms of viral, bacterial, and autoimmune encephalitis, and for protecting or reinforcing the blood-brain barrier, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A.

The present invention relates to pyridinyl derivatives of Formula (I) Formula (I) wherein R1, R2, R3, R4, R5, R6, Ar1, L, W, Z, m and n are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as LPA1 receptor modulators.

The present invention relates to compounds of formula (I), their synthesis and their use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders. [Formula 1] TIFF2023523300000191.tif51156

The present disclosure relates to compounds useful as proton activated G protein coupled receptor modulators and pharmaceutical compositions comprising the compounds. The present disclosure also relates to methods of using such compounds and pharmaceutical compositions to treat and / or prevent diseases, disorders or conditions mediated by proton activated G protein coupled receptors.

Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and / or diagnosis.

The present disclosure provides conjugates comprising at least one psychedelic compound or a precursor thereof and at least one N-methyl D-aspartate (NMD A) receptor (NMD AR) modulator or a precursor thereof, compositions comprising the same and uses thereof.

The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.

The present disclosure relates to a compound of formula (I), a stereoisomer, isotopically labeled compound, hydrate, solvate, or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, and a use thereof in the treatment of CXCR7-mediated diseases.

Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

A compound for use in the treatment of itch is provided, wherein the compound comprises the general formula (1a), general formula (1b) or general formula (1c). The compounds of the invention are positive allosteric α2 and / or α3 GABAA receptor modulators.

The invention discloses an orexin receptor modulator as well as a preparation method and application thereof, and particularly discloses an orexin receptor antagonist shown in the following formula. The orexin receptor antagonist provided by the invention can be used for treating nervous system related diseases. # imgabs0 #

In one aspect, the present application provides azabicyclo and diazepine derivatives useful as muscarinic receptor modulators. In another aspect, the present application provides pharmaceutical compositions for the treatment of ocular diseases, the compositions comprising at least one muscarinic receptor modulator. Formulas (I) and (II):

Abstract GPCR Receptor Agonists, Pharmaceutical Compositions Containing Them, and Methods of Use Thereof The application provides GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of administration thereof, and methods of use thereof for treatment and / or diagnosis. 010-9319-5532 / 1 / AMERICAS 010-9319-5532 / 1 / AMERICAS 48513847.1 1

The present invention features methods for reducing alcohol intake, intake of drugs of abuse, food intake, or to increase fat breakdown or lipolysis by administering a sphingosine-1-phosphate receptor modulator.

The present invention relates to an insecticidal and acaricidal composition. The composition contains active component A and active component B, wherein the active component A is selected from compound I; the active component B is selected from one or more of bionic juvenile hormones, chitin biosynthesis inhibitors affecting CHS1, type-1 chitin biosynthesis inhibitors, ecdysone receptor agonists, nicotinic acetylcholine receptor competitive modulators, ryanodine receptor modulators, nicotinic acetylcholine receptor allosteric modulators, glutamate-gated chloride channel allosteric modulators, sodium channel modulators, voltage-dependent sodium channel blockers, inhibitors, trifluoroethyl sulfide acaricides, other insecticides and acaricides, etc.; and the active component A has a structure as follows. The composition of the present invention has advantages such as obvious synergistic effects and delayed resistance development, and can be used for controlling a variety of pests.

Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable salt, homolog, hydrate or solvate thereof, wherein R is as defined herein. Such compounds serve as modulators of the sphingosine-1-phosphate receptor, and have utility for treatment of a malcondition for which activation of this receptor is medically indicated.

Disclosed in the present invention are an orexin receptor modulator, and a preparation method therefor and the use thereof, and specifically disclosed is an orexin receptor antagonist as shown in the following formula. The orexin receptor antagonist provided by the present invention can be used for treating diseases related to the nervous system.

The present disclosure provides azocino[4,5,6-cd]indoles as serotonin receptor modulators. Uses of said compounds in the treatment of medical disorders, such as neurological or psychiatric disorders, and processes of synthesizing said compounds are also provided.

Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and / or diagnosis.

Described herein, inter alia, are modulators of the Nurr1 receptor and uses thereof. In one aspect, provided is a method for treating a disease associated with dysregulation and / or degeneration of dopaminergic neurons of the central nervous system in a subject in need thereof, the method comprising administering to the subject in need thereof a therapeutically effective amount of a compound described herein.

The present invention relates to imidazo[1,2-a]pyridazine derivatives, a preparation method thereof, a pharmaceutical composition and uses thereof. The present invention provides a compound represented by formula (1), its stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, amorphous substances, isotopomers, polymorphs or solvates. A pharmaceutical composition containing the compound and the use of the compound as a GABA A receptor modulator, wherein R1, R2 and R3 are as defined in the specification.

The present disclosure provides compounds, such as compounds of Formula I, and their use in the treatment of medical diseases or disorders, such as psychiatric and nervous system diseases. Pharmaceutical compositions and methods of making various benzisoxazole and benzisothiazole compounds are provided. These compounds are considered to be modulators of the serotonin 2A (5-HT2A) receptor.

The present disclosure provides compounds, such as compounds of Formula I, and their use in the treatment of medical diseases or disorders, such as psychiatric and nervous system diseases. Pharmaceutical compositions and methods of making various benzisoxazole and benzisothiazole compounds are provided. These compounds are considered to be modulators of the serotonin 2A (5-HT2A) receptor.

This invention discloses compounds of Formula I or pharmaceutically acceptable salts thereof. Compounds of Formula I exhibit excellent S1PR1 receptor modulatory activity and high selectivity, thereby effectively avoiding potential cardiovascular toxicity while exerting immunomodulatory effects. The compounds and pharmaceutical compositions of this invention lay a solid chemical and biological foundation for the development of next-generation drugs targeting autoimmune diseases and specific malignant tumors, demonstrating promising clinical application prospects, social benefits, and potential industrialization value.

The invention relates to a steroidal compound as well as a preparation method and application thereof. Specifically, the invention provides a compound shown as a general formula (I), a stereoisomer or pharmaceutically acceptable salt of the compound, a preparation method of the compound, a pharmaceutical composition containing the compound and application of the compound as a GABAa receptor modulator to treatment of CNS-related diseases.

Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and / or diagnosis.

The present invention relates to the preparation of a SIP receptor modulator tauzimod ((R)-5-(2, 5-dichloro-4-(5-(8-chloro-6-(trifluoromethyl) imidazo [1, 2-a] pyridin-2-yl)-1, 2, 4-oxadiazol-3-yl) phenoxy) piperidin-2-one), and chemical intermediates used in the synthesis process of the SIP receptor modulator tauzimod ((R)-5-(2, 5-dichloro-4-(5-(8-chloro-6-(trifluoromethyl) imidazo [1, 2-a] pyridin-2-yl)-1, 2, 4-oxadiazol-3-yl) phenoxy) piperidin-2-one).

The present invention relates to a steroid derivative regulator, in particular to a compound of formula (I), a salt and crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effective amount of the crystal form, and an application thereof as a GABAA receptor regulator in treatment of depression, convulsions, Parkinsonism and nervous system diseases.

The present disclosure provides compounds, such as compounds of Formula I, and their use in the treatment of medical diseases or disorders, such as psychiatric and nervous system disorders. Pharmaceutical compositions and methods of making various tetrahydropyridine and piperidine compounds are provided. The compounds are expected to be modulators of the serotonin 2A (5-HT2A) receptor.